BENGALURU (Reuters) – Serum Institute Of India has applied to the country’s drug regulator and the health ministry for full market authorisation of its COVID-19 vaccine, Covishield, the company’s chief executive said in a tweet on Friday.
Serum Institute produces AstraZeneca’s COVID-19 vaccine under the brand name Covishield.
(Reporting by Shivani Singh in Bengaluru; Editing by Shounak Dasgupta)
